Co-Sponsors Highlight Important Research to be Presented at the 2013 Breast Cancer Symposium

For immediate release
September 6, 2013
Contact
Kate Blackburn
(571) 483-1379
Kate.Blackburn@asco.org

SAN FRANSISCO, CA - Five additional studies of note are among those that will be presented at the 2013 Breast Cancer Symposium, taking place September 7-9, 2013 at the San Francisco Marriott Marquis in San Francisco, California. Two studies examine cognitive function in women who undergo treatment for early-stage breast cancer; a third evaluates impact of tumor genotyping on clinical trial enrollment; and the final two evaluate the outcomes of different treatment approaches.

Saturday, September 7 Presentations

Abstract #48:
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.

General Poster Session A
Saturday, September 7, 2013, 11:30 AM – 1:00 PM PST
Saturday, September 7, 2013, 4:30 PM – 6:00 PM PST
Golden Gate Hall
Napa Parinyanitikul, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Abstract # 55:
Ten-year outcomes of accelerated partial breast irradiation compared with whole breast irradiation: A matched-pair analysis.

Poster Discussion A
Saturday, September 7, 2013, 4:00 PM – 4:20 PM PST
Yerba Buena Ballroom, Salon 8
Jessica Wobb, MD
Oakland University William Beaumont School of Medicine, Beaumont Cancer Institute
Royal Oak, MI

Sunday, September 8 Presentations

Abstract # 105:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM – 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Lara Heflin, PhD
New Mexico Highlands University
Las Vegas, NM

Abstract # 104:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM – 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Abstract # 145:
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.

Poster Discussion B
Sunday, September 8, 2013, 4:00 PM – 4:20 PM PST
Yerba Buena Ballroom, Salon 8

Aditya Bardia, MD
Massachusetts General Hospital,
Harvard Medical School
Boston, MA
Information for Media: www.asco.org/BCSpresskit

Oncologist-Approved Patient Information Resources from Cancer.Net, ASCO’s Cancer Information Website:

- Guide to Breast Cancer
- Breast Cancer Risk Factors
- Breast Cancer Prevention
- Understanding Cancer Risk
- ASCO’s Guideline on Drugs to Lower Breast Cancer Risk
- Understanding Statistics Used to Estimate Risk and Recommend Screening
- Understanding Radiation Therapy
- Understanding Cancer Surgery
- Side Effects of Radiation Therapy
- Frequently Asked Questions About Radiation Therapy
- Long-Term Side Effects of Cancer Treatment
- Coping With the Fear of Treatment-Related Side Effects
- Magnetic Resonance Imaging (MRI) – What to Expect
- Coping With Fear of Recurrence

An interactive history of cancer research advances, including those in breast cancer, can be found on ASCO’s Cancer Progress website at CancerProgress.Net.

2013 Breast Cancer Symposium News Planning Team
Dennis R. Holmes, M.D., FACS, American Society of Breast Disease (ASBD); Deanna J. Attai, MD, FACS, The American Society of Breast Surgeons; Steven O’Day, MD, American Society of Clinical Oncology (ASCO); Bruce G. Haffty, MD, FASTRO, American Society for Radiation Oncology (ASTRO); Anees B. Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C), The Society of Surgical Oncology (SSO), William R. Poller, MD, FACR, National Consortium of Breast Centers (NCBC).

Click here to view the disclosures for the News Planning Team.

About ASCO:
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.